Summit Therapeutics Inc. (SMMT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Summit Therapeutics Inc. (SMMT) is down 18.4% since the beginning of the year. At $14 per share, SMMT is trading 53.9% below its 52-week high of $31. Investors who bought $1,000 worth of SMMT shares 5 years ago would now be looking at an investment worth $2,207.

Summit Therapeutics Inc. (SMMT) has returned -18.35% so far this year and -30.54% over the past 12 months. Over the last ten years, SMMT has returned 5.97% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Mar 5, 2015, SMMT's average daily return is +0.29%, while the average monthly return is +5.38%. At this rate, an investment would double in approximately 1.1 years.

Historically, 45% of months were positive and 55% were negative. The best month was Dec 2022 with a return of +431.3%, while the worst month was Jun 2018 at -81.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, SMMT closed higher 46% of trading days. The best single day was May 30, 2024 with a return of +272.1%, while the worst single day was Jun 27, 2018 at -79.8%.

Summit Therapeutics Inc. has an annualized alpha of 89.94%, beta of 0.63, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since March 05, 2015.

• This stock captured 6.38% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -9.02%) - a profile typical of hedging or uncorrelated assets.
• Beta of 0.63 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SMMT ranks 26 for risk / return — below 26% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Summit Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Summit Therapeutics Inc. was 95.75%, occurring on Dec 1, 2022. Recovery took 443 trading sessions.

The current Summit Therapeutics Inc. drawdown is 61.09%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Summit Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Summit Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.